Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
44 hedge funds and large institutions have $3.3M invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 15 closing their positions.
10% less funds holding
Funds holding: 49 → 44 (-5)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
98% less capital invested
Capital invested by funds: $177M → $3.3M (-$174M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$509K |
| 2 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$248K |
| 3 |
Walleye Capital
New York
|
+$122K |
| 4 |
CAC
Cowen and Company
New York
|
+$108K |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$73.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.09M |
| 2 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$720K |
| 3 |
DPCM
Darlington Partners Capital Management
Greenbrae,
California
|
-$380K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$355K |
| 5 |
ClearBridge Investments
New York
|
-$351K |
DNA.WS Hedge Fund Activity: Q4 2022 in Review
44 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q4 2022, worth a combined $3.3M — down 98% from $177M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of DNA.WS and 11 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was LMR Partners, opening a new position worth an estimated $509K. The largest seller was Guggenheim Capital, cutting an estimated $2.09M.
- 44 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q4 2022, down from 49 in Q3 2022.
- Funds reported $3.3M of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q4 2022, down 98% quarter-over-quarter.
- 11 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q4 2022 and 15 closed out, a net change of -4 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q4 2022 was LMR Partners, an estimated $509K added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q4 2022 was Guggenheim Capital, an estimated $2.09M sold.
Based on aggregated 13F filings for Q4 2022.